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AbstrAct
background Adverse drug events (ADEs) are a leading cause of death in the 
United States. Patients with stage 3 and 4 chronic kidney disease (CKD) are at 
particular risk because many medications are cleared by the kidneys. Alerts in the 
electronic health record (EHR) about drug appropriateness and dosing at the time 
of prescription have been shown to reduce ADEs for patients with stage 3 and 4 
CKD in inpatient settings, but more research is needed about the implementation 
and effectiveness of such alerts in outpatient settings. 
Objective To explore factors that might inform the implementation of an electronic 
drug–disease alert for patients with CKD in primary care clinics, using Rogers’ diffu-
sion of innovations theory as an analytic framework.
Methods Interviews were conducted with key informants in four diverse clinics 
using various EHR systems. Interviews were audio recorded and transcribed. 
results Although all clinics had a current method for calculating glomerular filtra-
tion rate (GFR), clinics were heterogeneous with regard to current electronic deci-
sion support practices, quality improvement resources, and organizational culture 
and structure. 
conclusion Understanding variation in organizational culture and infrastructure 
across primary care clinics is important in planning implementation of an interven-
tion to reduce ADEs among patients with CKD.
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IntrOdUctIOn
Medical errors are the eighth leading cause of death in the 
United States1 and the most common form of medical error 
in inpatient settings, estimated at one medication error per 
patient per day.2 Patients in ambulatory care settings are also 
subject to medication errors, with one study documenting an 
overall medication error rate of 7.6%. Adverse drug events 
(ADEs) result in increased morbidity and mortality, increased 
cost, and excessive healthcare utilization.2–4 
Medication dosing errors and toxicity are especially impor-
tant and common problems in patients with chronic kidney 
disease (CKD).5,6 The incidence of ADEs is much higher in 
patients with CKD than those without CKD.7 Although stan-
dard dosing guidelines and methods of dose adjustment are 
available for patients with CKD,8 between 5.3% and 69.6% 
of medications that require dose adjustment are dosed inap-
propriately for patients with CKD.9–12
Two main strategies have been tested, almost exclusively 
in the inpatient setting, to assist practitioners in monitor-
ing and adjusting drug therapy among CKD patients: com-
puterised dosing programs and clinical pharmacist dosing 
 services.13,14 Use of these strategies can decrease dosing 
errors and the prescription of high-risk medications.15–18 We 
found only one study evaluating a computerised tool in the 
outpatient setting. Its results suggest that alerting outpatient 
pharmacists to possible errors in drug selection and dosing 
at the time of dispensing can decrease medication errors.19 
Computerised physician order entry (CPOE) is increas-
ingly used in ambulatory clinics to improve medication safety 
and quality of care.20 With the advent of incentive programs 
tied to meaningful use of an organization’s electronic health 
record (EHR), including effective decision support, a realistic 
strategy to improve medication management is to develop 
evidence-based alerts in ambulatory care that build on CPOE 
systems. An important next step is to evaluate whether this 
strategy can decrease dosing errors and other medication 
errors in the ambulatory care setting. 
This study explored how best to implement electronic 
drug–disease alerts for patients with CKD in four primary 
care clinics in the Northwest United States. Electronic drug–
disease alerts are computerised warnings at the time of pre-
scription that an EHR produces to alert a provider about the 
use of certain drugs in patients with specific conditions and 
diseases (Table 1). We recognized that working in a diverse 
set of community practices created heterogeneity of EHRs 
and numerous socio-technical factors. Research has docu-
mented that the process for planning implementation in a par-
ticular setting can be as important as the intervention itself.21 
We wanted to explore these socio-technical factors because 
we knew a single implementation strategy might not succeed 
equally across clinics. This project asked what key elements 
might increase the likelihood of success in implementing 
electronic drug–disease alerts for patients with CKD across 
diverse clinics. 
table 1 Glossary of acronyms and terms
Acronyms/Terms Definition
ADE Adverse drug event
CKD Chronic kidney disease
CPOE Computerised physician order entry
Drug-allergy alert A computerised warning at the time of 
prescription that an EHR produces to alert a 
provider about the potential for an adverse 
event related to the drug being prescribed 
and any allergies or adverse drug reactions 
recorded in the EHR.
Drug-disease alert A computerised warning at the time of 
prescription that an EHR produces to alert 
a provider about the use of certain drugs in 
patients with specific conditions and diseases.
Drug-drug alert A computerised warning at the time of 
prescription that an EHR produces to alert a 
provider about the interactions between the 
drug being prescribed and other drugs on the 
patient’s active medication list. 
Electronic alert Any computerised warning at the time of 
prescription, including drug-disease alerts, 
drug-drug alerts and drug allergy alerts.
QI Quality improvement
MethOds
Practice sites and selection
This study was conducted in the Washington, Wyoming, 
Alaska, Montana, and Idaho (WWAMI) region Practice and 
Research Network (WPRN), a practice-based research 
Keywords: adverse drug event (ADE), chronic kidney diseases (CKDs), 
electronic health records (EHRs), medication alert systems, outpatient clinic, 
primary care
What this paper adds
 • This paper provides guidance in planning to implement electronic drug–
disease alerts that warn providers about the use of certain drugs at the time of 
prescription for patients with specific diseases. 
 • EHR-based drug–disease alerts must be tailored to the resources, prescribing 
processes, organizational structures, and communication strategies at the 
primary care clinics adopting them to maximize acceptance.
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network in the five-state WWAMI region. We selected four 
WPRN clinics for this study based on the maturity of their 
EHR implementations and the ability to query the EHR. Two 
clinics are located in large cities (population >100,000) and 
two in smaller rural-serving cities. One clinic is hospital-affili-
ated, one university-affiliated, and the other two are commu-
nity health centers. The number of annual patient visits in the 
clinics ranges from roughly 17,000–50,000.
Framework application
We used Rogers’ diffusion of innovations (DOI) theory frame-
work for how new innovations are adopted by organizations 
and Greenhalgh’s subsequent work adapting the framework 
for healthcare settings.22,23 We used these frameworks to 
deductively explore factors that might help the intervention 
better diffuse in each clinic setting. The DOI framework, 
developed originally from studies in rural sociology, has been 
used frequently in healthcare settings, such as to implement 
metabolic syndrome screening guidelines24 and screening of 
mechanically ventilated patients for delirium.25
We focused on three of the four elements of the DOI 
framework most relevant to this study’s purpose: innovation, 
communication channels and social system (Table 2). Within 
innovation, we focused on three of the five characteristics of 
innovations that influence their adoption: compatibility, com-
plexity and relative advantage.
table 2 conceptual framework based on rogers’ dOI theory
Elements of DOI 
Framework Definition
Innovation A novel set of behaviors, routines and 
ways of working that are directed at 
improving health outcomes.
Compatibility
The degree to which the innovation is 
compatible with the intended adopters’ 
values, norms and perceived needs.
Complexity
The degree to which key players 
perceive the innovation as simple to use.
Relative advantage
The degree to which the innovation has 
a clear, unambiguous advantage to 
existing strategies
Communication channels The channels by which an innovation is 
spread.
Social system The system in which the innovation is 
spread.
Interview guide and interview procedures
We developed an interview guide (Appendix 1) that focused 
on understanding each clinic’s EHR capabilities, current 
availability of CKD-related decision support, organizational 
culture, organizational structure, and research and quality 
improvement (QI) infrastructure. Two study team members 
(JGB and CPL) conducted seven interviews with key infor-
mants at the four clinics, one team member leading while 
the other took notes. At each clinic, we interviewed a care 
provider able to describe the current state of CKD decision 
support and the clinic’s culture. At three sites, we also inter-
viewed an individual with specific knowledge of the clinic’s 
EHR system, as the care providers did not have the techno-
logical expertise to answer all interview questions. Four key 
informants were physicians, one a clinical pharmacist, one a 
director of quality, and one both a physician and director of 
clinical quality and population management. 
Six interviews were conducted in person, one by phone. All 
were recorded and transcribed. We gathered over 225 min 
of interviews resulting in 92 transcribed pages. Participants 
reviewed summaries of the interviews and corrected, clarified 
and/or supplemented the data as appropriate.
Analysis
The analysis mapped themes identified in the qualitative data 
to the DOI framework described above. Two coders (CPL 
and GK) developed a codebook based on the modified DOI 
framework. They used a deductive coding method starting 
with the DOI framework, then added open codes and recon-
ciled them with the framework. Each coder separately coded 
interviews using ATLAS.ti.26 The coders used an iterative 
process of reviewing and reconciling codes until agreement 
was reached. Other authors reviewed the primary coders’ 
themes and codes, verifying and augmenting them per their 
interpretation of the data. We received approval for this study 




We assessed compatibility (how well the innovation fits with 
the intended adopters’ values, norms and perceived needs) 
in three ways:
1. We compared the compatibility of the proposed 
intervention with the electronic alert capabilities at 
the clinics (Table 3). Of the four participating clinics, 
all had existing EHRs with the capability for drug–
disease alerts, but none had implemented these 
alerts. Sites 1, 3 and 4 had electronic alerts active 
in their EHR systems. Site 3 had limited its alerts to 
high-priority drug–drug and drug allergy alerts. 
2. We examined the clinics’ experience with and 
infrastructure for supporting research or QI projects. 
All four clinics had QI boards or processes. Sites 
2 and 3 had dedicated QI staff and commonly 
conducted QI projects using EHR data. 
3. We investigated whether the clinics intended to meet 
one of the stage 1 meaningful use core objectives 
by implementing drug–drug and drug allergy alerts. 
Meaningful use is a program that sets specific 
objectives that eligible professionals and hospitals 
must achieve to qualify for Centers for Medicare 
and Medicaid Services Incentive Programs.27 
Implementing drug–drug and drug allergy ‘interaction 
checks’ is a core objective for stage 1 meaningful 
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tons more buttons and they were in different locations… And 
while it gives more usability, it’s like shopping at Costco when 
you just want a small spice or something’. 
relative advantage
Relative Advantage is how well the innovation has a clear 
unambiguous advantage compared with existing strategies. 
Without electronic drug–disease alerts, providers are required 
either to know or to look up each medication at the time of 
prescribing to determine whether it requires dose adjustment 
or is contraindicated. This process generally involves several 
steps to access both the calculated glomerular filtration rate 
(GFR) from the chart and a database with information on 
medication renal dosing.
None of the clinics had CKD-related drug–disease alerts 
(Table 3). All of the clinics reported that they had a method 
to calculate GFR rates in the EHR or that laboratory reports 
return GFR calculations. Providers use this information at 
their discretion. 
communication
We looked at communication channels to understand how 
change was effected in each organization. Each clinic had a dif-
ferent culture of communication (Table 3). Site 2 regularly used 
team meetings with providers and nursing staff to communicate 
new information or initiatives. However, this method did not fully 
reach all of their staff: ‘One of the biggest problems that we 
have…is it’s just really hard to get everybody in the room and 
let them know what’s happening, not to mention your nurses. I 
mean even today, we’ve got one nurse sick and one nurse who’s 
off and we’re having our discussion about using [a new practice 
management tool]. So you can never capture everyone’.
For Site 1, clear communication was critical to its culture, 
with an emphasis on training for new initiatives: ‘the local 
hospital…recently implemented the CPOE process there 
without any training at all, and the providers were kind of up 
use. Sites 2 and 3 had already met meaningful use 
criteria using methods that did not involve electronic 
alerts. Site 4 reported that alerts might be part of their 
meeting meaningful use criteria, but that their alerts 
would need to be reviewed in order to do so, saying: 
‘we will probably reevaluate our alerts here relatively 
soon because we’re moving into meaningful use 
attestation… And my suspicion is that we will want to 
turn on a set of alerts for meaningful use. And it may 
be that in the process of doing that, we decide…we’d 
rather bother [providers] for pneumovax which is one 
of our requirements instead of this one’. 
complexity
Complexity is the degree to which the innovation is perceived 
as difficult to use. Alert fatigue, the process of receiving too 
many alerts, causing the receiver to ignore alerts,28 emerged 
as a common concern among all the key informants inter-
viewed: ‘So the biggest barrier that I can think of is…alert 
fatigue… we all see an alert virtually every single time we 
enter the EMR, of one kind or another and you know, this 
would be just one more alert. But I do think that at least at this 
point in time, there are not many of our alerts that are really 
patient oriented…’
Key informants also discussed the importance of the alert 
fitting into their workflows, or being ‘useful’, ‘relevant’ or ‘time 
saving’. For example, one participant shared, ‘I think the ques-
tion is when it flags you. I know early on they turned on some 
things that popped up as soon as you logged in and those really 
weren’t that helpful. It needs to happen around the time you’re 
ordering’. Another noted, ‘I think it’s going to be a welcome 
function as long as it doesn’t complicate current prescribing 
practices. If they can be seamlessly integrated into [the EHR 
system] without multiple additional clicks, I think it would be a 
very welcome piece’. One participant gave an example of a 
new EHR feature that did not have these traits, ‘[there were] 
table 3 Key results by the dOI framework
Site 1 Site 2 Site 3 Site 4
Innovation: compatibility Patient-level alerts – drug–
drug and drug allergy
No patient-level alerts High priority drug–drug and 
drug allergy only
Patient-level alerts – drug–
drug and drug allergy
Innovation: complexity All participants recommended 
alerts that do not impede 




GFR values, no CKD  
drug–disease alert 
GFR values, no CKD  
drug–disease alert
GFR values, no CKD  
drug–disease alert
GFR values, no CKD drug–
disease alert
Communication channels Training Team meetings with all staff Email No standard
Social system Lead clinic of small multi-
clinic organization. Strong 
role in decision making but 
must work with the other 
clinics.
Stand-alone clinic, decision 
making is all done locally.
Part of large health system. 
Decision making at higher 
levels.
Part of large health system. 
Decision-making at higher 
levels.
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It is critical that we tailor an implementation plan for each 
organization to these factors to maximize acceptance. The 
DOI framework can be used to guide the design of an imple-
mentation plan for a CKD electronic drug–disease alert.
Implications of the findings
Compatibility with Clinic Values, Norms and Needs
There was substantial variability in the availability of elec-
tronic alerts in the four participating clinics. In a clinic without 
alerts, providers would not be accustomed to interruptions or 
stops to their prescribing workflow and the proposed inter-
vention might represent a fundamental change, leading to 
potential disruption and rejection.29 For these clinics, the 
implementation plan would need to be designed in a way that 
specifically addressed the introduction of electronic drug–dis-
ease alerts and any resulting shift in provider workflow.
One clinic had a robust QI infrastructure that could sup-
port long-term evaluation and follow-up. At the clinics that 
had limited QI resources, it would be critical to ensure that 
the necessary resources would be available for follow-up and 
monitoring CKD drug–disease alerts. 
We thought that making the proposed intervention part of a 
larger QI effort such as meaningful use might be an incentive 
to potential partner clinics. However, we discovered that sev-
eral had already met meaningful use criteria using methods 
that did not involve electronic alerts, and a third had other 
higher priority alerts to implement. Meaningful use standards 
may still serve as a possible incentive towards implementing 
an alert-based intervention, but clearly our approach must be 
tailored to each clinic.
Complexity of the intervention
This study found that the intervention must fit into a clinician’s 
existing workflow, saving time and being efficient. This rein-
forces the importance of making sure that an intervention can 
meet these requirements before engaging with the clinics. 
Additionally, when working with the clinics, we must evaluate 
the intervention using these criteria to show the clinics that 
we understand their priorities and to ensure better long-term 
acceptance. Our key informants made clear that an alert that 
would require significant workflow redesign at the level of the 
provider alert interface would serve as a barrier to its use. 
Relative advantage compared with existing 
strategies
The proposed intervention would use the available GFR 
data in the EHR to identify patients with CKD and, for these 
patients, alert the provider with a pop up window at the time 
that a contraindicated drug or inappropriate drug dose was 
prescribed. The pop up window would support the provider 
by warning about drug contraindications for patients with 
CKD and by recommending drug doses or frequencies that 
fit the patient’s level of kidney function. This introduces new 
clinical functions (e.g. identification of patients previously not 
identified with CKD and recommended changes in drug dos-
ing based on GFR) and a new delivery method for this infor-
mation (pop up window). Thus, the proposed intervention 
in arms over that, you know, they were very clear about-do 
not do that here’.
Sites 3 and 4 had a more ‘hands off’ approach to com-
munication. Site 3 primarily used email to communicate and 
did not require approval from providers prior to implementing 
EHR changes. At this clinic, providers were accustomed to 
learning about new functions through their everyday use of 
the EHR. Key informants from site 4 also reported that their 
clinic has no standard method for communicating change. 
social system
We examined the social system at each clinic, focusing on 
how decisions were made, which is integral to how quickly 
an innovation will be adapted. The clinics that are members 
of larger health systems had top-down management and 
decision making, whereas the other clinics had much more 
local decision-making authority (Table 3). For instance, site 
2 is an independent clinic whose information technology was 
managed on-site by clinic-employed personnel. Therefore, 
all of its EHR customizations and implementations could be 
conducted locally, including provider-level customizations. 
Site 2’s key informant shared an example of provider-level 
customization, ‘you open up one of Dr … ’s patients that he 
is designated as the PCP (primary care provider) on? It will 
say basically, …call me. Don’t monkey with my patients too 
much’.
In contrast, sites 3 and 4 are members of large health sys-
tems with centralized information technology systems, staff 
and committees. EHR-related decisions were made for the 
entire health care system rather than for individual clinics. 
Physicians from site 3 reported that they were accustomed 
to new features appearing in the EHR without their direct 
involvement in the decision-making process. Site 4’s orga-
nization had recently implemented a new policy that any 
changes to the EHR must be system wide, rather than on a 
clinic-by-clinic basis. ‘So in the early days we could build all 
our own templates, we could do whatever, and now there’s… 
We’re becoming the battleship that’s slowly turning and no 
longer little speedboats’.
Site 1 is the largest clinic in a small network of clinics. This 
clinic hosted administrative committees and thus had a lead 
role in making decisions about EHR changes. This clinic was 
both similar to site 2 in its ability to drive change at a local 
level and subject to some of the same collective decision-
making policies of the larger health systems.
Clinical pharmacists are one resource to promote and sup-
port an alert-based intervention. All but one clinic employed 




This study discovered that the proposed CKD drug–disease 
alert was variably compatible with resources and prescribing 
processes at four primary care clinics, which had a wide vari-
ety of organizational structures and communication cultures. 
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the effectiveness of individual alert features. Practice-based 
research networks that include multiple clinics with EHR 
capabilities, sometimes within larger health systems, provide 
a robust environment in which to implement experiments of 
these features.34,35
lIMItAtIOns OF the stUdY
We interviewed at most two key informants at each clinic 
and thus did not receive multiple perspectives from the same 
organization. Because this preliminary research did not focus 
on the willingness of the clinics to engage in implementing 
this intervention, but rather on the socio-technical charac-
teristics of each setting, we felt that these informants could 
accurately represent their clinics. 
cOnclUsIOn
Rogers’ DOI theory provided a useful framework for explor-
ing factors that might influence the implementation of a CKD 
drug–disease alert in four community-based primary care 
clinics. Rogers describes organizational culture as ‘how 
things are done’. This work shows that how things are done 
in community-based primary care settings can vary greatly, 
especially in terms of decision making and  communication 
to providers. Given these findings, it is not surprising that 
clinics that are provided practice facilitators to assist with 
tailored clinical redesign and QI are significantly more 
likely to change their clinical practices than clinics without 
facilitators.36,37 Those who implement new interventions 
in these settings, whether informatics based or not, must 
be conscious of clinic differences, understand how they 
might impact their implementation planning and tailor 
the  interventions to different clinical settings in order to 
 maximize the chances of acceptance. 
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would add new capabilities and necessitate culture change at 
each of the clinics, since there were no existing drug–disease 
alerts. It would be critical to emphasize the benefit of this new 
type of alert and the advantage over current methods to the 
clinics and their providers.
Communication channels and social system
Understanding clinics’ existing communication and social 
systems allows development of individualized communica-
tion strategies for each setting. We discovered two general 
types of staff communication channels: face-to-face all-staff 
meetings and communication to staff via electronic means 
such as emails. Thus, an implementation plan for an alert-
based intervention would best include support for multiple 
communication and information dissemination methods. 
This study suggests that different sites may be more accus-
tomed to or expect use of certain communication channels. 
Supporting multiple approaches should provide the needed 
flexibility to respect clinic culture when choosing information 
dissemination methods while being sensitive to the informa-
tion overload already facing clinicians. 
comparison with Previous research
Like this study, Bates et al.30 found that an intervention must 
fit into the existing workflow, saving time, being efficient and 
changing direction rather than forcing a hard stop in work. 
They also recommend continuous maintenance of alerts to 
reflect current evidence and to monitor the usage pattern of 
alerts. Though alerts can be an important tool for improving 
drug safety,31 Cho et al.32 have demonstrated that providers 
do not heed (‘override’) the recommendations in alerts for 
renal dosing of medications most of the time, and only about 
30% of these overrides are appropriate. A small number of 
providers were responsible for a large proportion of the over-
rides. This suggests that alerts must be accompanied by other 
interventions to ensure success. Kawamoto et al.’s33 system-
atic review of trials using clinical decision support systems to 
improve clinical practice identified features that predicted the 
success of these systems, including integration into clinician 
workflow at the time and location of decision making and provi-
sion of recommendations rather than assessments only.
call for Further research
Electronic drug–disease alerts have the potential to include 
the features that Kawamoto et al.33 identified as predictive 
of success, yet additional research is needed to directly test 
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APPendIX 1. IntervIeW GUIde
Thank you for agreeing to this telephone interview today as part of our pilot project on improving safe prescribing practices in 
patients with chronic kidney disease (CKD). 
Specifically, we plan to create an EMR alert that will advise providers when they are prescribing drugs that require renal dose 
adjustment or that are contraindicated in patients with CKD – this alert will be in real time while the prescription is being signed 
electronically.
1. CKD alert
1.1.  How would you feel about this alert? (Interview introduction explaining the CKD alert intervention omitted in this 
appendix) 
1.2. What types of barriers might arise during implementation and might prevent full utilization? 
1.3.  What would your fellow physicians think about this intervention?  
What barriers or challenges do you see to this future project, especially at your site?
2. General EMR experience
2.1. What electronic medical record is available at your practice?
2.2. What other health software packages do you use (e.g. billing, scheduling and specialty software)?
2.3. How many years has that electronic medical record been in the practice?
2.4. Are there any plans to change EMRs in the next 1–3 years?
2.5. Have there been major changes to your EMR in the past 1–3 years?
2.6.  Who is the current EMR support staff at the practice? What EMR support is available outside of the practice? 
(e.g. who do you call when you need help with EMR problems?)
2.7.  What are the examples of implementation of EMR-based quality improvement (QI) and research initiatives 
completed in this clinic in the past 1–2 years? (e.g. examples of when you used your EMR to collect data and 
improve the quality of care provided in your practice?)
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2.8.  For what clinical scenarios does your EMR prompt you to do something (order test, laboratory, med) or not to do 
something (drug–drug interactions and allergies)? For what processes are EMR alerts available? (define EMR 
alerts: drug–drug interactions, allergies, disease–drug contraindications and drug dosing) What percentage of 
the time that you are using an EMR during a patient visit does one of these prompts appear?
2.9. Is there a particular type of alert that you find to be most useful/least useful?
2.10.  Are there any EMR alerts, flags or decision support tools currently available that specifically relate to patients 
with CKD? If yes, please describe. 
2.11.  What clinical decision support tools (e.g. calculators for dosing and risk assessment [Gail, Framingham]) 
and links to external evidence-based websites [e.g. NIH, CDC and US Preventive Services Task Force] are 
available?
2.12. Does your EMR laboratory result calculate and report glomerular filtration rate?
3. Governance and operational questions
3.1.  Describe how your clinic operates within a larger system (e.g. free standing clinic, part of university system of 
clinics, part of community clinics, network of private practices)?
3.2.  When changes are implemented to your EMR, can that change be directed specifically to individual providers or 
individual clinics?
3.3. By what processes are EMR alerts developed and implemented in the practice? 
3.4. What personnel are required for design, approval and implementation? 
3.5.  How are innovative clinical protocols vetted in your institution (e.g. quality committee)? Is there a queue, triage 
process? By what approval process are they implemented? 
3.6.  Are you aware of any evaluation process after the implementation of EMR alerts? Is there an updating process 
or quality check process after implementation? How have EMR-based initiatives been evaluated at your clinic? 
Who/what is responsible for this evaluation process?
4. EMR QI/research experience history
4.1. What CKD-related QI or research initiatives have been completed in the past 5 years at the clinic site?
4.2.  How does the clinic expect to meet the meaningful use objective to implement drug–drug and drug allergy 
interaction checks (or have they already)?
4.3.  Does your clinic have specific guidelines or protocols or EMR decision support or curricula around CKD safe 
prescribing?
4.4.  How does your EMR currently identify prescribing safety issues or adverse drug events/prescribing errors/
contraindications/dosing issues and relative contraindications (e. g. registry, pharmacist, EMR alert)?
